T2 Biosystems Performance
| TTOODelisted Stock | USD 0.18 0.05 21.74% |
The firm owns a Beta (Systematic Risk) of 6.94, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, T2 Biosystems will likely underperform. T2 Biosystems today owns a risk of 0.0%. Please validate T2 Biosystems total risk alpha, as well as the relationship between the kurtosis and market facilitation index , to decide if T2 Biosystems will be following its current price history.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days T2 Biosystems has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, T2 Biosystems is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 11.9 M |
TTOO |
T2 Biosystems Relative Risk vs. Return Landscape
If you would invest 0.00 in T2 Biosystems on December 20, 2024 and sell it today you would earn a total of 0.00 from holding T2 Biosystems or generate 0.0% return on investment over 90 days. T2 Biosystems is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than TTOO, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
T2 Biosystems Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for T2 Biosystems' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as T2 Biosystems, and traders can use it to determine the average amount a T2 Biosystems' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| TTOO |
Based on monthly moving average T2 Biosystems is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of T2 Biosystems by adding T2 Biosystems to a well-diversified portfolio.
T2 Biosystems Fundamentals Growth
TTOO Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of T2 Biosystems, and T2 Biosystems fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on TTOO Pink Sheet performance.
| Return On Equity | -6.22 | ||||
| Return On Asset | -0.9 | ||||
| Operating Margin | (4.91) % | ||||
| Current Valuation | 21.91 M | ||||
| Shares Outstanding | 21.04 M | ||||
| Price To Earning | (2.04) X | ||||
| Price To Book | 14.50 X | ||||
| Price To Sales | 0.69 X | ||||
| Revenue | 7.19 M | ||||
| EBITDA | (43.88 M) | ||||
| Cash And Equivalents | 13.21 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 49.5 M | ||||
| Debt To Equity | 6.64 % | ||||
| Book Value Per Share | (6.91) X | ||||
| Cash Flow From Operations | (48.14 M) | ||||
| Earnings Per Share | (0.03) X | ||||
| Total Asset | 34.8 M | ||||
| Retained Earnings | (584.3 M) | ||||
| Current Asset | 77.78 M | ||||
| Current Liabilities | 18.54 M | ||||
About T2 Biosystems Performance
By examining T2 Biosystems' fundamental ratios, stakeholders can obtain critical insights into T2 Biosystems' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that T2 Biosystems is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts. T2 Biosystems operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 182 people.Things to note about T2 Biosystems performance evaluation
Checking the ongoing alerts about T2 Biosystems for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for T2 Biosystems help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| T2 Biosystems is not yet fully synchronised with the market data | |
| T2 Biosystems has some characteristics of a very speculative penny stock | |
| T2 Biosystems has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.19 M. Net Loss for the year was (50.08 M) with loss before overhead, payroll, taxes, and interest of (24.77 M). | |
| T2 Biosystems currently holds about 13.21 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 74.0% of the company shares are owned by institutional investors |
- Analyzing T2 Biosystems' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether T2 Biosystems' stock is overvalued or undervalued compared to its peers.
- Examining T2 Biosystems' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating T2 Biosystems' management team can have a significant impact on its success or failure. Reviewing the track record and experience of T2 Biosystems' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of T2 Biosystems' pink sheet. These opinions can provide insight into T2 Biosystems' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Other Consideration for investing in TTOO Pink Sheet
If you are still planning to invest in T2 Biosystems check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the T2 Biosystems' history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |